Neuralab Limited
28Patents
0Active
28Granted
34Portfolio score
Filing activity: Nov 30, 1998 → Sep 2, 2004
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6743427B1 | Prevention and treatment of amyloidogenic disease | Chemistry; Metallurgy | 159 | Expired |
| US6761888B1 | Passive immunization treatment of Alzheimer's disease | Chemistry; Metallurgy | 127 | Expired |
| US6787637B1 | N-Terminal amyloid-&bgr; antibodies | Chemistry; Metallurgy | 113 | Expired |
| US6750324B1 | Humanized and chimeric N-terminal amyloid beta-antibodies | Physics | 108 | Expired |
| US7179892B2 | Humanized antibodies that recognize beta amyloid peptide | Chemistry; Metallurgy | 100 | Expired |
| US6913745B1 | Passive immunization of Alzheimer's disease | Physics | 99 | Expired |
| US6875434B1 | Methods of treatment of Alzheimer's disease | Physics | 94 | Expired |
| US6972127B2 | Prevention and treatment of amyloidogenic disease | Chemistry; Metallurgy | 93 | Expired |
| US6787523B1 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 91 | Expired |
| US6710226B1 | Transgenic mouse assay to determine the effect of A&bgr; antibodies and A&bgr; Fragments on alzheimer's disease characteristics | Physics | 84 | Expired |
| US6866849B2 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 81 | Expired |
| US6787139B1 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 79 | Expired |
| US6787138B1 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 79 | Expired |
| US6787144B1 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 78 | Expired |
| US6787140B1 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 77 | Expired |
| US6866850B2 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 73 | Expired |
| US7189819B2 | Humanized antibodies that recognize beta amyloid peptide | Chemistry; Metallurgy | 72 | Expired |
| US6905686B1 | Active immunization for treatment of alzheimer's disease | Chemistry; Metallurgy | 69 | Expired |
| US6890535B1 | Pharmaceutical compositions and methods for treatment of amyloid diseases | Physics | 69 | Expired |
| US6787143B1 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 68 | Expired |
| US7014855B2 | Prevention and treatment of amyloidogenic disease | Chemistry; Metallurgy | 67 | Expired |
| US6962707B2 | Prevention and treatment of amyloidogenic disease | Emerging Cross-Sectional Technologies | 50 | Expired |
| US6982084B2 | Prevention and treatment of amyloidogenic disease | Chemistry; Metallurgy | 49 | Expired |
| US6946135B2 | Prevention and treatment of amyloidogenic disease | Chemistry; Metallurgy | 45 | Expired |
| US6923964B1 | Active immunization of AScr for prion disorders | Chemistry; Metallurgy | 43 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.